Experienced in Undifferentiated Connective Tissue Disease (UCTD)

Dr. Kenneth C. Kalunian

Rheumatology
Regents Of The University Of California
200 W Arbor Dr, 
San Diego, CA 
Offers Telehealth
Experienced in Undifferentiated Connective Tissue Disease (UCTD)
Regents Of The University Of California
200 W Arbor Dr, 
San Diego, CA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Kenneth Kalunian is a Rheumatologist in San Diego, California. Dr. Kalunian is rated as an Experienced provider by MediFind in the treatment of Undifferentiated Connective Tissue Disease (UCTD). His top areas of expertise are Systemic Lupus Erythematosus (SLE), Lupus Nephritis, Cutaneous Lupus Erythematosus (CLE), Synovectomy, and Endoscopy.

His clinical research consists of co-authoring 144 peer reviewed articles and participating in 6 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Rheumatology
Licenses
Internal Medicine in CA
Hospital Affiliations
Uc San Diego Health Hillcrest - Hillcrest Med Ctr
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
CareFirst
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Community Health Group
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Health Net

Accepted plan types not found. Please verify directly with the provider.

Highmark
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Oscar
  • EPO
  • HMO
  • PPO
Premera Blue Cross
  • INSURANCE PLAN
  • MEDICARE MAPD
  • OTHER COMMERCIAL
  • PPO
SCAN Health Plan
  • INSURANCE PLAN
  • MEDICARE MAPD
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 15 Less Insurance Carriers -

Locations

REGENTS OF THE UNIVERSITY OF CALIFORNIA
200 W Arbor Dr, San Diego, CA 92103

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

6 Clinical Trials

A Phase II Controlled Trial of Allogeneic Mesenchymal Stem Cells for the Treatment of Refractory Lupus
A Phase II Controlled Trial of Allogeneic Mesenchymal Stem Cells for the Treatment of Refractory Lupus
Enrollment Status: Active_not_recruiting
Publish Date: August 21, 2025
Intervention Type: Drug
Study Drugs: Low Dose Mesenchymal Stem Cells, High Dose Mesenchymal Stem Cells
Study Phase: Phase 2
A Phase 2 Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of VIB7734 for the Treatment of Moderate to Severely Active Systemic Lupus Erythematosus
A Phase 2 Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of VIB7734 for the Treatment of Moderate to Severely Active Systemic Lupus Erythematosus
Enrollment Status: Completed
Publish Date: July 23, 2024
Intervention Type: Drug, Other
Study Drug: VIB7734
Study Phase: Phase 2
A 2-Part Phase 2 Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of BIIB059 in Subjects With Systemic Lupus Erythematosus and Active Skin Manifestations and in Subjects With Active Cutaneous Lupus Erythematosus With or Without Systemic Manifestations
A 2-Part Phase 2 Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of BIIB059 in Subjects With Systemic Lupus Erythematosus and Active Skin Manifestations and in Subjects With Active Cutaneous Lupus Erythematosus With or Without Systemic Manifestations
Enrollment Status: Completed
Publish Date: November 07, 2023
Intervention Type: Drug
Study Phase: Phase 2
A Phase 2, Double-blind, Randomized, Placebo-controlled Multicenter Study to Evaluate Efficacy, Safety, and Tolerability of JBT-101 in Systemic Lupus Erythematosus
A Phase 2, Double-blind, Randomized, Placebo-controlled Multicenter Study to Evaluate Efficacy, Safety, and Tolerability of JBT-101 in Systemic Lupus Erythematosus
Enrollment Status: Completed
Publish Date: November 18, 2022
Intervention Type: Drug
Study Drug: JBT-101
Study Phase: Phase 2
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 3 Trial to Evaluate Efficacy and Safety of Lenabasum in Dermatomyositis
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 3 Trial to Evaluate Efficacy and Safety of Lenabasum in Dermatomyositis
Enrollment Status: Completed
Publish Date: August 16, 2022
Intervention Type: Drug
Study Drug: Lenabasum
Study Phase: Phase 3
An Investigator-Initiated, Phase II, Randomized, Withdrawal Study of Mycophenolate Mofetil (MMF) in Patients With Stable, Quiescent Systemic Lupus Erythematosus (SLE)
An Investigator-Initiated, Phase II, Randomized, Withdrawal Study of Mycophenolate Mofetil (MMF) in Patients With Stable, Quiescent Systemic Lupus Erythematosus (SLE)
Enrollment Status: Terminated
Publish Date: August 17, 2020
Intervention Type: Drug
Study Phase: Phase 2
View 5 Less Clinical Trials

144 Total Publications

The interferon response signature links to increased expression of transposable elements in neutrophils of systemic lupus erythematosus patients.
The interferon response signature links to increased expression of transposable elements in neutrophils of systemic lupus erythematosus patients.
Journal: bioRxiv : the preprint server for biology
Published: June 12, 2025
Similar Doctors
Advanced in Undifferentiated Connective Tissue Disease (UCTD)
Dr. Surabhi A. Khanna
Rheumatology
Advanced in Undifferentiated Connective Tissue Disease (UCTD)
Dr. Surabhi A. Khanna
Rheumatology

Emergency And Acute Care Medical Corporation

7901 Frost St, 
San Diego, CA 
 (3.2 miles away)
858-939-3400
Languages Spoken:
English, Hindi
See accepted insurances
Accepting New Patients
Offers Telehealth

Surabhi Khanna is a Rheumatologist in San Diego, California. Dr. Khanna is rated as a Distinguished provider by MediFind in the treatment of Undifferentiated Connective Tissue Disease (UCTD). Her top areas of expertise are Systemic Sclerosis (SSc), Scleroderma, Scleroma, Rheumatoid Arthritis (RA), and Gastrostomy. Dr. Khanna is currently accepting new patients.

Advanced in Undifferentiated Connective Tissue Disease (UCTD)
Dr. Alexander R. Shikhman
Rheumatology
Advanced in Undifferentiated Connective Tissue Disease (UCTD)
Dr. Alexander R. Shikhman
Rheumatology

Institute For Specialized Medicine Inc

4125 Sorrento Valley Blvd, Suite A, 
San Diego, CA 
 (10.7 miles away)
858-794-9192
Languages Spoken:
English
See accepted insurances

Alexander Shikhman is a Rheumatologist in San Diego, California. Dr. Shikhman is rated as an Advanced provider by MediFind in the treatment of Undifferentiated Connective Tissue Disease (UCTD). His top areas of expertise are Sjogren Syndrome, Lyme Disease, Undifferentiated Connective Tissue Disease (UCTD), and Rheumatoid Vasculitis.

Advanced in Undifferentiated Connective Tissue Disease (UCTD)
Dr. Puja Chitkara
Rheumatology
Advanced in Undifferentiated Connective Tissue Disease (UCTD)
Dr. Puja Chitkara
Rheumatology

Puja Chitkara, Md, A Medical Corporation

765 Medical Ctr Ct, Suite 216, 
Chula Vista, CA 
 (12.6 miles away)
619-623-3000
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Puja Chitkara is a Rheumatologist in Chula Vista, California. Dr. Chitkara is rated as a Distinguished provider by MediFind in the treatment of Undifferentiated Connective Tissue Disease (UCTD). Her top areas of expertise are Rheumatoid Arthritis (RA), Mixed Connective Tissue Disease, MASS Phenotype, and Polymyalgia Rheumatica.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Kalunian's expertise for a condition
ConditionClose
View All 9 Advanced Conditions
View All 36 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile